Bank of New York Mellon’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,010,099
| Closed | -$59.3M | – | 4383 |
|
|
2023
Q4 | $59.3M | Buy |
1,010,099
+817,394
| +424% | +$46M | 0.01% | 934 |
|
|
2023
Q3 | $8.39M | Buy |
192,705
+9,340
| +5% | +$333K | ﹤0.01% | 2043 |
|
|
2023
Q2 | $6.62M | Buy |
183,365
+13,101
| +8% | +$540K | ﹤0.01% | 2165 |
|
|
2023
Q1 | $6.33M | Buy |
170,264
+1,308
| +0.8% | +$58.8K | ﹤0.01% | 2169 |
|
|
2022
Q4 | $7.66M | Sell |
168,956
-6,247
| -4% | -$404K | ﹤0.01% | 2087 |
|
|
2022
Q3 | $12.2M | Sell |
175,203
-467,090
| -73% | -$34.6M | ﹤0.01% | 1780 |
|
|
2022
Q2 | $43.1M | Buy |
642,293
+484,014
| +306% | +$30.8M | 0.01% | 1088 |
|
|
2022
Q1 | $13M | Sell |
158,279
-10,001
| -6% | -$1.02M | ﹤0.01% | 1932 |
|
|
2021
Q4 | $24.7M | Buy |
168,280
+7,886
| +5% | +$1.22M | ﹤0.01% | 1595 |
|
|
2021
Q3 | $28.4M | Sell |
160,394
-22,120
| -12% | -$3.56M | 0.01% | 1513 |
|
|
2021
Q2 | $29.5M | Buy |
182,514
+23,020
| +14% | +$3.7M | 0.01% | 1511 |
|
|
2021
Q1 | $27.3M | Sell |
159,494
-34,052
| -18% | -$6.74M | 0.01% | 1525 |
|
|
2020
Q4 | $42.5M | Buy |
193,546
+37,787
| +24% | +$8.17M | 0.01% | 1146 |
|
|
2020
Q3 | $25.9M | Buy |
155,759
+7,159
| +5% | +$980K | 0.01% | 1302 |
|
|
2020
Q2 | $17M | Buy |
148,600
+24,393
| +20% | +$2.37M | ﹤0.01% | 1547 |
|
|
2020
Q1 | $9.55M | Sell |
124,207
-156
| -0.1% | -$14K | ﹤0.01% | 1726 |
|
|
2019
Q4 | $16M | Buy |
124,363
+5,767
| +5% | +$556K | ﹤0.01% | 1700 |
|
|
2019
Q3 | $9.24M | Sell |
118,596
-7,646
| -6% | -$718K | ﹤0.01% | 1975 |
|
|
2019
Q2 | $13M | Buy |
126,242
+14,122
| +13% | +$1.1M | ﹤0.01% | 1807 |
|
|
2019
Q1 | $8.22M | Buy |
112,120
+15,460
| +16% | +$1.05M | ﹤0.01% | 2075 |
|
|
2018
Q4 | $4.1M | Sell |
96,660
-10,656
| -10% | -$425K | ﹤0.01% | 2416 |
|
|
2018
Q3 | $5.05M | Sell |
107,316
-2,822
| -3% | -$157K | ﹤0.01% | 2407 |
|
|
2018
Q2 | $5.43M | Buy |
110,138
+85,595
| +349% | +$3.23M | ﹤0.01% | 2347 |
|
|
2018
Q1 | $753K | Buy |
24,543
+6,847
| +39% | +$190K | ﹤0.01% | 3368 |
|
|
2017
Q4 | $323K | Buy |
17,696
+1,761
| +11% | +$27.3K | ﹤0.01% | 3771 |
|
|
2017
Q3 | $186K | Buy |
15,935
+1,186
| +8% | +$6.86K | ﹤0.01% | 3891 |
|
|
2017
Q2 | $54K | Sell |
14,749
-48,255
| -77% | -$185K | ﹤0.01% | 4120 |
|
|
2017
Q1 | $328K | Buy |
63,004
+11,753
| +23% | +$64.4K | ﹤0.01% | 3725 |
|
|
2016
Q4 | $244K | Sell |
51,251
-3,043
| -6% | -$16.6K | ﹤0.01% | 3838 |
|
|
2016
Q3 | $359K | Sell |
54,294
-6,578
| -11% | -$35K | ﹤0.01% | 3692 |
|
|
2016
Q2 | $332K | Sell |
60,872
-231
| -0.4% | -$3.68K | ﹤0.01% | 3710 |
|
|
2016
Q1 | $1.31M | Buy |
61,103
+5,075
| +9% | +$113K | ﹤0.01% | 2907 |
|
|
2015
Q4 | $1.77M | Sell |
56,028
-1,023
| -2% | -$36.1K | ﹤0.01% | 2792 |
|
|
2015
Q3 | $1.96M | Buy |
57,051
+21,885
| +62% | +$662K | ﹤0.01% | 2755 |
|
|
2015
Q2 | $1.11M | Buy |
35,166
+12,448
| +55% | +$367K | ﹤0.01% | 3281 |
|
|
2015
Q1 | $666K | Buy |
22,718
+2,094
| +10% | +$49.1K | ﹤0.01% | 3487 |
|
|
2014
Q4 | $382K | Sell |
20,624
-517
| -2% | -$8.72K | ﹤0.01% | 3713 |
|
|
2014
Q3 | $370K | Sell |
21,141
-34
| -0.2% | -$635 | ﹤0.01% | 3722 |
|
|
2014
Q2 | $424K | Buy |
+21,175
| New | +$409K | ﹤0.01% | 3653 |
|
Other funds holding MRTX
Bank of New York Mellon's MRTX Position: Q1 2024 in Review
Bank of New York Mellon sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,010,099 shares — an estimated $59.3M sold.
Bank of New York Mellon first reported a position in MRTX in Q2 2014 and held it in 39 quarters. The position peaked at $59.3M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Bank of New York Mellon reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Bank of New York Mellon sold 1,010,099 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $59.3M.
- Bank of New York Mellon first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 39 quarters.
- Bank of New York Mellon's Mirati Therapeutics, Inc. Common Stock position peaked at $59.3M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.